Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
5/2005 | Tranzyme | Series A | - |
3/2019 | Kaarta | Series A | 0 |
11/2008 | Helomics | Venture Round | 43M |
7/2008 | NuPathe | Series B | 30M |
8/2007 | EKR Therapeutics | Series C | 13M |
10/2007 | Optherion | Series A | 37M |
4/2008 | Diasome Pharmaceuticals | Series B | 8.4M |
4/2007 | StageMark | Series B | 1.6M |
8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
1/2011 | RainDance Technologies | Series D | 37.5M |
10/2009 | Sleep Solutions | Series F | 20M |
10/2008 | Biolex Therapeutics | Series D | 0 |
11/2007 | Tranzyme | Venture Round | 20M |
10/2009 | Neuronetics | Series D | 0 |
9/2012 | Intact Vascular | Series A | 15.5M |
5/2005 | Celator Pharmaceuticals | Series B | 20M |
12/2009 | Regado Biosciences | Series D | 0 |
8/2003 | Biolex Therapeutics | Venture Round | 0 |
3/2006 | Nitric Bio | Series A | 14M |
10/2008 | Corridor Pharmaceuticals | Seed Round | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
6/2007 | Argolyn Bioscience | Series A | 15.8M |
11/2008 | Tengion | Series C | 0 |
4/2004 | MedMark Treatment Centers | Venture Round | 28M |
4/2013 | RainDance Technologies | Series E | 0 |
12/2002 | BioRexis | Series A | 8M |
3/2007 | Regado Biosciences | Series C | 23M |
6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
3/2006 | Helomics | Venture Round | 20M |
6/2010 | Helomics | Series D | 33M |
8/2009 | Rapid Micro Biosystems | Series A | 18.6M |
6/2011 | NovaSom | Series D | 35M |
3/2008 | EKR Therapeutics | Series D | 50M |
1/2010 | Tarsa Therapeutics | Series A | 24M |
2/2005 | Neotropix | Series A | 10M |
3/2004 | BioRexis | Series B | 30M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
10/2007 | Tengion | Series C | 33M |
8/2007 | Celator Pharmaceuticals | Series C | 10M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
6/2006 | Tengion | Series B | 50M |
5/2010 | TearScience | Series C | 44.5M |
1/2010 | BioLeap | Series A | 5M |
4/2005 | TargetRx | Series D | 0 |
6/2004 | Nucleonics | Series B | 49.2M |
9/2005 | Amicus Therapeutics | Series C | 55M |
4/2015 | Neuronetics | Series F | 0 |
8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
6/2009 | Cempra | Series C | 46M |
5/2011 | Neuronetics | Series E | 30M |
6/2010 | Corridor Pharmaceuticals | Series A | 0 |
9/2005 | Biolex Therapeutics | Series B | 36M |
5/2007 | Biolex Therapeutics | Series C | 30M |
3/2012 | Tarsa Therapeutics | Series B | 28M |
9/2006 | Amicus Therapeutics | Series D | 60M |
4/2008 | Transave | Series D | 35M |
3/2019 | Kaarta | Series A | 0 |
4/2015 | Neuronetics | Series F | 0 |
9/2013 | PreCision Dermatology | Debt Financing | 0 |
4/2013 | RainDance Technologies | Series E | 0 |
9/2012 | Intact Vascular | Series A | 0 |
3/2012 | Tarsa Therapeutics | Series B | 0 |
6/2011 | NovaSom | Series D | 0 |
5/2011 | Neuronetics | Series E | 0 |
1/2011 | RainDance Technologies | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|